35018-17-8

Basic information

• Product Name: 2-(2,2-diMethylpyrrolidin-1-yl)ethanaMine
• Synonyms: 2-(2,2-diMethylpyrrolidin-1-yl)ethanaMine;EOS-60579
• CAS NO: 35018-17-8
• Molecular Formula: C₈H₁₈N₂
• Molecular Weight: 142.24192
• EINECS: -0
• Mol File: 35018-17-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2,2-diMethylpyrrolidin-1-yl)ethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2-diMethylpyrrolidin-1-yl)ethanaMine(35018-17-8)
• EPA Substance Registry System: 2-(2,2-diMethylpyrrolidin-1-yl)ethanaMine(35018-17-8)

Safety Data

• Hazardous Substances Data: 35018-17-8(Hazardous Substances Data)

Usage

Chemical Class

Secondary amines

Physical State

Clear, colorless liquid

Odor

Faint

Usage

Synthesis of pharmaceuticals and other organic compounds, precursor in drug production

Known for

Increasing bioavailability of certain drugs in the body

Industry

Pharmaceutical research and development

Handling

Hazardous if not used properly

Downstream Products

• 1426531-23-8 N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426531-26-1 7-bromo-N-(5-(2-(2,2-dimethylpyrrolidin-1-yl)ethylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1226916-88-6 N-[2-(2,2-Dimethylpyrrolidin-1-yl)ethyl]-5-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]pyridine-2-amine 

Relevant articles and documents

Aryl compounds with aminoalkyl substituents and their use

The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.